The related presentation, entitled "In Vivo and In Vitro Activity of DAS181 Against NAI-Resistant Influenza Virus" examined the in vivo and in vitro activity of DAS181 against patient isolates of community-acquired seasonal influenza from the 2008-2009 influenza season. All isolates had the H274Y mutation associated with resistance to Tamiflu. DAS181 in vitro was an effective inhibitor of Tamiflu-resistant influenza virus. In addition, in vivo mouse challenge studies with another NAI-resistant strain demonstrated strong sensitivity to DAS181 treatment.

Both studies are presented by Ronald Moss M.D., Executive Vice President, Clinical Development and Medical Affairs. "Based on these encouraging data we are moving forward with our ongoing clinical development of DAS181, and we will continue to work closely with FDA, CDC, and NIH on this clinical program during the current pandemic," stated Dr. Moss. "Because of viral evolution, alternatives to current treatment strategies are needed to deal with potential drug resistance. DAS181 may play an important role for public health preparedness during influenza pandemics."

Source: nexbio